详情页 - 河北大学附属医院知识库

当前位置：首页 > 详情页

Development of glioblastoma organoids and their applications in personalized therapy

16| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：重点期刊

作者：

机构： [1]School of Clinical Medicine,Hebei University,Department of Neurosurgery,Affiliated Hospital of Hebei University,Baoding 07100,China. [2]School of Basic Medical Sciences, Hebei University, Baoding 07100, China. [3]Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China. [4]Department of Pathology,Affiliated Hospital of Hebei University,Baoding 07100,China.

出处：

DOI：

ISSN：

关键词： Glioblastoma organoids glioma stem cell drug screening

摘要：

Glioblastomas (GBMs) are the brain tumors with the highest malignancy and poorest prognoses. GBM is characterized by high heterogeneity and resistance to drug treatment. Organoids are 3-dimensional cultures that are constructed in vitro and comprise cell types highly similar to those in organs or tissues in vivo, thus simulating specific structures and physiological functions of organs. Organoids have been technically developed into an advanced ex vivo disease model used in basic and preclinical research on tumors. Brain organoids, which simulate the brain microenvironment while preserving tumor heterogeneity, have been used to predict patients' therapeutic responses to antitumor drugs, thus enabling a breakthrough in glioma research. GBM organoids provide an effective supplementary model that reflects human tumors' biological characteristics and functions in vitro more directly and accurately than traditional experimental models. Therefore, GBM organoids are widely applicable in disease mechanism research, drug development and screening, and glioma precision treatments. This review focuses on the development of various GBM organoid models and their applications in identifying new individualized therapies against drug-resistant GBM.Copyright © 2023 Cancer Biology & Medicine.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 2 区医学

小类 | 2 区医学：研究与实验 2 区肿瘤学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区医学：研究与实验 2 区肿瘤学

JCR分区：

出版当年[2023]版：

Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 ONCOLOGY

最新[2023]版：

Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 ONCOLOGY

影响因子： 5.6 最新[2023版] 5.9 最新五年平均 5.6 出版当年[2023版] 5.9 出版当年五年平均 5.5 出版前一年[2022版]

第一作者：

第一作者机构： [1]School of Clinical Medicine,Hebei University,Department of Neurosurgery,Affiliated Hospital of Hebei University,Baoding 07100,China.

共同第一作者：

通讯作者：

通讯机构： [1]School of Clinical Medicine,Hebei University,Department of Neurosurgery,Affiliated Hospital of Hebei University,Baoding 07100,China. [2]School of Basic Medical Sciences, Hebei University, Baoding 07100, China. [3]Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China. [4]Department of Pathology,Affiliated Hospital of Hebei University,Baoding 07100,China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Halofuginone Sensitizes Lung Cancer Organoids to Cisplatin via Suppressing PI3K/AKT and MAPK Signaling Pathways [2]Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition [3]A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma [4]Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma [5]idh野生型胶质母细胞瘤的组织病理特征及分子病理特征分析 [6]RUNX1 contributes to the mesenchymal subtype of glioblastoma in a TGFβ pathway-dependent manner [7]TGFβ signaling-induced miRNA participates in autophagic regulation by targeting PRAS40 in mesenchymal subtype of glioblastoma [8]MiRNA-154-5p inhibits cell proliferation and metastasis by targeting PIWIL1 in glioblastoma [9]Virtual mutagenesis of isocitrate dehydrogenase 1 involved in glioblastoma multiforme [10]Pro-inflammatory and proliferative microglia drive progression of glioblastoma.